Compare BOC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOC | DRUG |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.9M | 364.8M |
| IPO Year | 2017 | N/A |
| Metric | BOC | DRUG |
|---|---|---|
| Price | $12.23 | $76.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $25.00 | ★ $83.00 |
| AVG Volume (30 Days) | ★ 184.7K | 168.9K |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $112,601,970.00 | N/A |
| Revenue This Year | $6.06 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.22 | N/A |
| 52 Week Low | $11.30 | $23.18 |
| 52 Week High | $15.75 | $97.75 |
| Indicator | BOC | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 50.05 |
| Support Level | $12.30 | $77.80 |
| Resistance Level | $12.76 | $89.71 |
| Average True Range (ATR) | 0.33 | 7.83 |
| MACD | -0.12 | -1.56 |
| Stochastic Oscillator | 1.25 | 6.58 |
Boston Omaha Corp is a United States based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. Company generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.